172 related articles for article (PubMed ID: 11332155)
1. Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice.
Langer SW; Sehested M; Jensen PB
Ann Oncol; 2001 Mar; 12(3):405-10. PubMed ID: 11332155
[TBL] [Abstract][Full Text] [Related]
2. Treatment of anthracycline extravasation with dexrazoxane.
Langer SW; Sehested M; Jensen PB
Clin Cancer Res; 2000 Sep; 6(9):3680-6. PubMed ID: 10999761
[TBL] [Abstract][Full Text] [Related]
3. Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone.
Langer SW; Thougaard AV; Sehested M; Jensen PB
Cancer Chemother Pharmacol; 2006 Jan; 57(1):125-8. PubMed ID: 16001176
[TBL] [Abstract][Full Text] [Related]
4. The use of dexrazoxane for the prevention of anthracycline extravasation injury.
Hasinoff BB
Expert Opin Investig Drugs; 2008 Feb; 17(2):217-23. PubMed ID: 18230055
[TBL] [Abstract][Full Text] [Related]
5. Dexrazoxane use in the prevention of anthracycline extravasation injury.
Hasinoff BB
Future Oncol; 2006 Feb; 2(1):15-20. PubMed ID: 16556068
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
7. Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane.
Langer SW; Thougaard AV; Sehested M; Jensen PB
Cancer Chemother Pharmacol; 2012 Feb; 69(2):573-6. PubMed ID: 22143379
[TBL] [Abstract][Full Text] [Related]
8. The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells.
Hasinoff BB; Yalowich JC; Ling Y; Buss JL
Anticancer Drugs; 1996 Jul; 7(5):558-67. PubMed ID: 8862724
[TBL] [Abstract][Full Text] [Related]
9. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species.
Wu X; Hasinoff BB
Anticancer Drugs; 2005 Jan; 16(1):93-9. PubMed ID: 15613911
[TBL] [Abstract][Full Text] [Related]
10. Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin.
Hofland KF; Thougaard AV; Sehested M; Jensen PB
Clin Cancer Res; 2005 May; 11(10):3915-24. PubMed ID: 15897593
[TBL] [Abstract][Full Text] [Related]
11. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies.
Mouridsen HT; Langer SW; Buter J; Eidtmann H; Rosti G; de Wit M; Knoblauch P; Rasmussen A; Dahlstrøm K; Jensen PB; Giaccone G
Ann Oncol; 2007 Mar; 18(3):546-50. PubMed ID: 17185744
[TBL] [Abstract][Full Text] [Related]
12. Extravasation accidents with liposomal/liposomal pegylated anthracyclines treated with dexrazoxane: an overview and outcomes.
Caballero Romero Á; Delgado Ureña MT; Salmerón García A; Megías Fernández MT; Librada Porriño-Bustamante M; Cabeza Barrera J
Anticancer Drugs; 2018 Oct; 29(9):821-826. PubMed ID: 30036190
[TBL] [Abstract][Full Text] [Related]
13. Successful experience utilizing dexrazoxane treatment for an anthracycline extravasation.
Tyson AM; Gay WE
Ann Pharmacother; 2010 May; 44(5):922-5. PubMed ID: 20371757
[TBL] [Abstract][Full Text] [Related]
14. A murine experimental anthracycline extravasation model: pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damage.
Thougaard AV; Langer SW; Hainau B; Grauslund M; Juhl BR; Jensen PB; Sehested M
Toxicology; 2010 Feb; 269(1):67-72. PubMed ID: 20079798
[TBL] [Abstract][Full Text] [Related]
15. Dexrazoxane (ICRF-187).
Weiss G; Loyevsky M; Gordeuk VR
Gen Pharmacol; 1999 Jan; 32(1):155-8. PubMed ID: 9888268
[TBL] [Abstract][Full Text] [Related]
16. Catalytic inhibitors of topoisomerase II differently modulate the toxicity of anthracyclines in cardiac and cancer cells.
Vavrova A; Jansova H; Mackova E; Machacek M; Haskova P; Tichotova L; Sterba M; Simunek T
PLoS One; 2013; 8(10):e76676. PubMed ID: 24116135
[TBL] [Abstract][Full Text] [Related]
17. Treatment of anthracycline extravasation with dexrazoxane -- clinical experience.
Frost A; Gmehling D; Azemar M; Unger C; Mross K
Onkologie; 2006 Jul; 29(7):314-8. PubMed ID: 16874015
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.
Hasinoff BB; Kuschak TI; Creighton AM; Fattman CL; Allan WP; Thampatty P; Yalowich JC
Biochem Pharmacol; 1997 Jun; 53(12):1843-53. PubMed ID: 9256159
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the protective effects of amifostine and dexrazoxane against the toxicity of doxorubicin in spontaneously hypertensive rats.
Herman EH; Zhang J; Chadwick DP; Ferrans VJ
Cancer Chemother Pharmacol; 2000; 45(4):329-34. PubMed ID: 10755322
[TBL] [Abstract][Full Text] [Related]
20. Successful dexrazoxane treatment of a potentially severe extravasation of concentrated doxorubicin.
Conde-Estévez D; Saumell S; Salar A; Mateu-de Antonio J
Anticancer Drugs; 2010 Sep; 21(8):790-4. PubMed ID: 20671512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]